# Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update
Ticker: LCTX
Company: Lineage Cell Therapeutics
Source: Lineage Cell Therapeutics
Published: 2026-03-05 21:01 EST
Original Source URL: https://investor.lineagecell.com
## Summary

Positive RG6501 (OpRegen ®   Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements

## Article Body
Positive RG6501 (OpRegen ®   Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements
## Recent Company News
- 2026-05-12 20:01 EST — [Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Lineage Cell Therapeutics
- 2026-05-05 12:00 EST — [Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026) — Source: Lineage Cell Therapeutics
- 2026-05-04 12:00 EST — [OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026](https://biopharmsignal.com/news/LCTX/opregenr-3-year-results-in-patients-with-ga-presented-at-foundation-fighting-blindness-retinal-innovation-summit-2026) — Source: Lineage Cell Therapeutics
- 2026-04-13 12:00 EST — [Lineage Announces Formation of Scientific Advisory Board](https://biopharmsignal.com/news/LCTX/lineage-announces-formation-of-scientific-advisory-board) — Source: Lineage Cell Therapeutics
- 2026-03-24 12:00 EST — [Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease](https://biopharmsignal.com/news/LCTX/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease) — Source: Lineage Cell Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)